Loading...
A226950 logo

OliX Pharmaceuticals, IncKOSDAQ:A226950 Stock Report

Market Cap ₩1.8t
Share Price
₩91.70k
My Fair Value
1Y429.1%
7D-2.4%
Portfolio Value
View

OliX Pharmaceuticals, Inc

KOSDAQ:A226950 Stock Report

Market Cap: ₩1.8t

OliX Pharmaceuticals (A226950) Stock Overview

A clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. More details

A226950 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

A226950 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

US$5.3
70.2% undervalued intrinsic discount
Revenue growth
N/A
Profit Margin
30%
Future PE
20x
Share price in 2030
US$0

OliX Pharmaceuticals, Inc Competitors

Price History & Performance

Summary of share price highs, lows and changes for OliX Pharmaceuticals
Historical stock prices
Current Share Price₩91,700.00
52 Week High₩107,500.00
52 Week Low₩13,380.00
Beta0.85
1 Month Change12.10%
3 Month Change146.17%
1 Year Change429.14%
3 Year Change351.72%
5 Year Change164.65%
Change since IPO179.57%

Recent News & Updates

Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Jul 07
Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Mar 21
Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Recent updates

Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Jul 07
Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Mar 21
Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

The Price Is Right For OliX Pharmaceuticals, Inc (KOSDAQ:226950) Even After Diving 27%

Jan 29
The Price Is Right For OliX Pharmaceuticals, Inc (KOSDAQ:226950) Even After Diving 27%

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump

Dec 07
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump

OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

Nov 15
OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Oct 09
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

Aug 22
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25
It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13
OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17
Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Shareholder Returns

A226950KR BiotechsKR Market
7D-2.4%1.6%4.5%
1Y429.1%21.7%34.3%

Return vs Industry: A226950 exceeded the KR Biotechs industry which returned 21.7% over the past year.

Return vs Market: A226950 exceeded the KR Market which returned 34.3% over the past year.

Price Volatility

Is A226950's price volatile compared to industry and market?
A226950 volatility
A226950 Average Weekly Movement13.3%
Biotechs Industry Average Movement7.3%
Market Average Movement4.9%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A226950's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A226950's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
201066Dong-Ki Leewww.olixpharma.com

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia.

OliX Pharmaceuticals, Inc Fundamentals Summary

How do OliX Pharmaceuticals's earnings and revenue compare to its market cap?
A226950 fundamental statistics
Market cap₩1.84t
Earnings (TTM)-₩45.14b
Revenue (TTM)₩7.54b
244.7x
P/S Ratio
-40.9x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A226950 income statement (TTM)
Revenue₩7.54b
Cost of Revenue₩286.45m
Gross Profit₩7.25b
Other Expenses₩52.39b
Earnings-₩45.14b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.24k
Gross Margin96.20%
Net Profit Margin-598.92%
Debt/Equity Ratio116.8%

How did A226950 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/04 03:43
End of Day Share Price 2025/10/02 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OliX Pharmaceuticals, Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.